Chapter 4 : A New Growth Stage
Based on the expertise it had accumulated in the prescription ophthalmic
market in Japan, Santen began establishing a foothold in overseas markets.
Santen now has eleven operational bases in seven countries overseas, including
the United States, Germany and Finland.
|
|
1993
|
|
U.S. subsidiary Santen Inc. established
Santen Inc.conducts the R&D, business development
and strategic marketing activities in the U.S.
|
|
1994
|
|
Santen GmbH established in Germany
Santen GmbH started sales operations in Germany in 2002
with the launch of the anti-infective ophthalmic
Oftaquix
(brand
name in Japan:
Cravit
).
|
|
1995
 |
Hyalein |
|
|
Hyalein, a treatment for corneal disorders, launched in Japan
Hyalein
is a unique drug that repairs damage
to the corneal epithelium resulting from dry eye syndrome. In the six years
since its launch, sales had exceeded 10 billion yen.
Anti-rheumatic drug Azulfidine EN launched in Japan
Beijing Representative Office opened
|
|
| 1996 |
|
Nara Research and Development Center and Shiga Plant opened
|
|
|
Nara R&D Center |
|
|
|
Shiga Plant |
|
|
1997
|
Santen Oy |
|
|
Acquisition of a Finnish ophthalmic pharmaceutical company and the subsequent establishment of Santen Oy
With
the establishment of Santen Oy, Santen gained its first overseas production
base and made its entry into the Northern and Eastern European markets.
Taiwan Santen Pharmaceutical Co., Ltd. established
|
|
| 1998 |
|
Medium-term plan "Hitomi 21" devised |
|
2000
|
Cravit |
|
|
Anti-infective ophthalmic Cravit launched in Japan
Cravit
has become the first-choice treatment
for eye infections for its strong anti-infective action and excellent ability
to penetrate ophthalmic tissue.
Santen Pharmaceutical Korea, Co., Ltd. and Guangzhou Representative Office established
In June 2000, Santen received a threat regarding tampering
with its over-the-counter eye drops. Concerned for the safety of consumers,
Santen disclosed the information immediately and withdrew all its over-the-counter
products from the market.
|
|
2001
|
Detantol |
|
|
Detantol, a treatment for glaucoma and ocular hypertension, and Livostin, an anti-allergy ophthalmic solution, launched in Japan
Acquisition of the U.S.-based Advanced Vision Science, Inc.
Advanced
Vision Science, Inc. is an ophthalmic medical device manufacturer with strong
capabilities in the research and development of intraocular lenses.
|
|
2002
|
Dimple Bottle |
|
|
Introduced the Dimple Bottle
|
|
| 2003 |
|
2003-2005 Medium-term Management Plan devised
|
|
| 2005 |
|
Shanghai Representative office established
Santen Pharmaceutical(China) Co., Ltd. establishedd
|
|
| 2006 |
|
PAPILOCK Mini ophthalmic solution 0.1%, a treatment for vernal keratoconjunctivitis, launched in Japan
2006-2010 Medium-term Management Plan devised
|
|
|
Prev
|
